BioMarin Pharmaceutical reported Q1 2026 revenues of $766 million, up 3% year-over-year, driven by increased demand for enzyme therapies and new patients on VOXZOGO. Following its acquisition of Amicus Therapeutics, BioMarin raised its full-year 2026 revenue guidance to $3.825-$3.925 billion, reflecting a 20% growth rate at the midpoint. The company highlighted strong pipeline progress, including FDA approvals and upcoming Phase 3 data readouts, positioning it for continued innovation and growth. Despite higher expenses related to the acquisition and R&D, BioMarin expects improved financial performance and expanded patient reach in rare diseases.
Golden Heaven Group Holdings Ltd. and several defendants have agreed to a $1.7 million settlement in a class action lawsuit related to the company's 2023 IPO and subsequent stock purchases. The settlement, approved by the New York Supreme Court, cove...
Kaltura has won the Best Event AI Technology award at Eventex 2026 for the fourth consecutive year, highlighting its leadership in AI-driven event solutions. This year, Kaltura's new Agentic Avatars, which provide real-time, personalized conversation...
Taseko Mines Limited announced a proposal to change its name to Trekor Metals Limited at its upcoming Annual General Meeting on June 24, 2026. The name change aims to reflect the company's expanded asset base and growth in North America’s copper sect...
LuxUrban Hotels Inc. has reached a $3 million settlement in a class action lawsuit approved by the U.S. District Court for the Southern District of New York. The settlement covers purchasers of LuxUrban's common and preferred stock between May 9, 202...
Smithfield Foods contributed $150,000 to Operation Homefront to aid military and veteran families through transitional housing and holiday meal programs. This funding supports rent-free housing, financial counseling, and food assistance, helping fami...
